ASCENT – Asthma control in severe asthma patients treated with tezepelumab: a prospective, observational, real-world evidence study

Purpose of trial

Healthcare is aware of the importance of patient important outcomes data in the real-world in order to complement results from randomised clinical trials. This study will assess the impact of tezepelumab treatment as per the participant’s perspective on asthma symptom control, lung function, health-related quality of life, and key patient-reported outcomes in a real-world setting.

ASCENT will assess asthma symptom control, lung function, and patient-reported outcomes after starting tezepelumab treatment. Patient-reported outcomes are increasingly being used to assess patient experience and impact with disease and treatment, as there can be a disconnect between effects of treatment on objective measures of disease versus patient-reported outcomes.

Eligibility

• Participant must be 19 years or older at the time of signing the consent form
• They must be prescribed treatment with tezepelumab according to label and local reimbursement criteria
• They must have a diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses
• They must have had at least one prescription of medium- to high-dose ICS during the 52 weeks prior to enrolment date
• They must have used an additional asthma maintenance controller medication(s) in addition to ICS for at least 52 weeks prior to enrolment date.
• They must have a documented history of at least one asthma exacerbation during the 52 weeks prior to enrolment date
• Further criteria will be discussed

Resources

National Library of Medicine trial link